Baseline characteristics
| Group 1: improvers (n = 26) | Group 2: non-improvers (n = 24) | p Value | |
|---|---|---|---|
| Data are mean (SD) or number (%). | |||
| *Assessed by radionuclide ventriculography. | |||
| †Derived by the ratio of left ventricular (LV) short to long axis dimensions in the apical four chamber view.15 | |||
| ACE, angiotensin converting enzyme; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NS, not significant; NYHA, New York Heart Association. | |||
| Men | 22 (85%) | 18 (75%) | NS |
| Age (years) | 62 (12) | 60 (12) | NS |
| Previous MI | 24 (92%) | 24 (100%) | NS |
| Q wave MI | 20 (83%) | 21 (87)% | NS |
| Anterior MI | 14 (54%) | 15 (62%) | NS |
| NYHA class | 3.15 (0.8) | 2.96 (0.7) | NS |
| CCS class | 2.57 (0.7) | 2.67 (0.6) | NS |
| Stenotic vessels | 2.4 (0.7) | 2.7 (0.6) | NS |
| Smoking | 12 (46%) | 14 (58%) | NS |
| Hypertension | 22 (85%) | 21 (87%) | NS |
| Hypercholesterolaemia | 16 (61%) | 13 (54%) | NS |
| Family history of CAD | 13 (50%) | 16 (67%) | NS |
| Diabetes mellitus | 1 (5%) | 2 (8%) | NS |
| Lipid lowering drugs | 13 (50%) | 10 (42%) | NS |
| ACE inhibitors | 17 (65%) | 19 (79%) | NS |
| Nitrates | 22 (85%) | 19 (79%) | NS |
| β Blockers | 16 (61%) | 16 (67%) | NS |
| Diuretics | 12 (46%) | 16 (67%) | NS |
| Digoxin | 4 (15%) | 7 (29%) | NS |
| Aspirin/anticoagulant | 26 (100%) | 22 (92%) | NS |
| LVEF (%)* | 33 (10) | 32 (7) | NS |
| LV end diastolic volume (ml) | 160 (59) | 194 (39) | <0.05 |
| LV end systolic volume (ml) | 105 (49) | 135 (37) | <0.05 |
| LV sphericity index† | 0.58 (0.09) | 0.61 (0.11) | NS |